300+ investors in your industry, stage, and region Get
Any industry
Google
Clean Energy
EdTech
Artificial Intelligence
Local
Enterprise Software
Travel
Platforms
InsurTech
Retail
Oil and Gas
Social Impact
Cryptocurrency
SaaS
Film
Restaurants
Photography
Payments
Email
CleanTech
Energy
Marketplace
Organic Food
Fitness
Machine Learning
Health Care
Agriculture (AgTech)
Gaming
Facebook
Social Network
Blockchain
B2B
Video Games
Big Data
Medical Device
Wellness
Education
Mobile
Automotive
Sports
Legal
eSports
Construction
Hospitality
Biotechnology
Consumer
Software
Renewable Energy
Crowdfunding
Venture Capital
Fashion
Social
Beauty
Infrastructure
Cannabis
LGBT
Celebrity
Climate
Mobile Apps
Life Science
Wine and Spirits
Food and Beverage
Theatre
Publishing
Music
Art
Real Estate
Sporting Goods
Medical
Manufacturing
Digital Media
FinTech
Recruiting
Finance
Financial Services
Social Media
Franchise
Web3
Mobile Advertising
Non Profit
Android
Internet
Sustainability
Hardware
Biotech
Impact
Proptech
Enterprise
Transportation
Community
Media (Entertainment)
Any country
Hong Kong
Thailand
United Arab Emirates
Egypt
Greece
Croatia
Burkina Faso
South Korea
Singapore
Brazil
Kyrgyzstan
LATAM
Africa
Oceania
Gibraltar
Liberia
Taiwan
Tunisia
Mexico
Sweden
Nigeria
Russian Federation
Togo
Zimbabwe
Guinea
Nepal
Zambia
Iran
Isle of Man
Norway
Madagascar
Pakistan
Tajikistan
Romania
Poland
Oman
Puerto Rico
Andorra
Cameroon
Guernsey
Sudan
Colombia
China
Armenia
Czech Republic
Costa Rica
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Mauritius
Nicaragua
Panama
Namibia
Serbia
Uzbekistan
New Zealand
Australia
Saudi Arabia
Sri Lanka
Jamaica
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Malawi
Myanmar
Uganda
Turkey
Uruguay
Morocco
Moldova
Paraguay
Seychelles
Botswana
Ireland
Japan
South Africa
France
Georgia
Denmark
Ghana
Iraq
Canada
Mali
Latvia
Malaysia
United Kingdom
Portugal
Philippines
Sierra Leone
Rwanda
El Salvador
Senegal
Tanzania
United States
Germany
India
Indonesia
Middle East
Asia
Dominican Republic
Bermuda
Spain
Albania
Argentina
Angola
Bangladesh
Europe
Cyprus
Belgium
Barbados
Jordan
Austria
Ethiopia
Azerbaijan
Bulgaria
Ecuador
Bahamas
Faroe Islands
Estonia
Jersey
Bahrain
Bolivia
Algeria
Belize
Finland
Italy
Belarus
Hungary
Grenada
Israel
Iceland
Cambodia
Honduras
Lithuania
Liechtenstein
Lebanon
Mongolia
Qatar
Peru
Slovenia
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
Genome British Columbia, VC Fund

Genome British Columbia

VC Fund

Vancouver, Canada

Genome British Columbia is a VC fund in Vancouver focused on Health Care and Biotechnology. Genome BC, a non-profit research organization, leads genomics innovation on Canada’s West Coast and facilitates the integration of genomics into society. Their major investors are the Province of British Columbia and the Government of Canada through Genome Canada and Western Economic Diversification Canada. This funding is complemented bypartnerships with many national and international public and private funding organizations to drive BC’s bioeconomy.

Total investments:
12
Last investment:
Lead investor:
67%

Last updated:

Industries Genome British Columbia invests in

Health CareBiotechnologyMedical DeviceMedicalTherapeutics

Stages Genome British Columbia invests in

SeedGrantSeries BVenture - Series Unknown

Countries Genome British Columbia invests in

Canada

Round sizes

Seed $1.8M–$4.7M

Contacts

NameEmailPhoneSocials

Sign up to unlock verified contacts

Unlock Contacts

2 more contacts available

Round size

Seed
$1.8M–$4.7M

Investment Focus

Industry

  • Health Care 6 (50%)
  • Biotechnology 3 (25%)
  • Medical Device 3 (25%)
  • Medical 2 (17%)
  • Therapeutics 2 (17%)
See all 24 industries →

Stage

  • Seed 7 (58%)
  • Grant 3 (25%)
  • Series B 1 (8%)
  • Venture - Series Unknown 1 (8%)

Team

NameTitleInvestmentsLinksEmail
Tony Brooks CFO& VP Entrepreneurship & Commercialization
CFO& VP Entrepreneurship & Commercialization Total investments: 3
Find email
Catalina Lopez-Correa
Catalina Lopez-Correa Chief Scientific Officer & Vice President Sectors
Chief Scientific Officer & Vice President Sectors Total investments: 0 Find email
Federica Di Palma
Federica Di Palma Chief Scientific Officer and Vice President Sectors
Chief Scientific Officer and Vice President Sectors Total investments: 1
Find email

Investments

CompanyDescriptionRoundLinks
BugSeq Bioinformatics BugSeq Bioinformatics
BugSeq is leveraging advanced sequencing technologies to revolutionize infectious disease testing and pathogen surveillance. BugSeq’s analysis suite delivers unparalleled data analytics and industry-leading expertise to convert sequencing data into actionable results. By profiling tens of thousands of microorganisms and markers of antimicrobialresistance from any specimen, BugSeq enables broad adoption of sequencing to improve health. Grant / Jul 08, 2026
CereCura Nanotherapeutics CereCura Nanotherapeutics
CereCura Nanotherapeutics is developing novel RNA therapeutics for central nervous system disorders. Grant / Aug 06, 2025
Verdi Verdi
Verdi is building the data science platform for hyper-specific farm actions, starting with irrigation. $4.7M / Seed / May 15, 2025
Verdi Expeditions Verdi Expeditions
Verdi Expeditions is a scalable platform for agricultural automation and tailored plant health. $4.7M / Seed / May 15, 2025
Arbutus Medical Arbutus Medical
Every hospital in the world is faced with a major challenge - the rising cost of heathcare - we want to do something about it. Arbutus Medical’s purpose is to develop a portfolio of “frugal innovation” devices that save costs for hospitals and improve access to orthopedic surgery for 5 million patients by 2030. Arbutus Medical's flagshipproduct is a radically affordable orthopaedic power tool system that is used in North American Trauma Centers, veterinary hospitals, military deployments, NGO missions, and hospitals in over 30 low- and middle-income countries worldwide. $2.3M / Seed / Feb 13, 2023
Avivo Biomedical Avivo Biomedical
Avivo Biomedical operates as a preclinical-stage company, has identified enzymes that convert the cell surface antigens that determine a person’s blood group to group O, the universal donor type. $250K / Grant / Mar 31, 2022
LightIntegra Technology LightIntegra Technology
LightIntegra Technology is a privately funded medical diagnostics company and launched from the Canadian Blood Services R&D labs through the efforts of research scientist Dr. Elisabeth Maurer. LightIntegra strives to minimize platelet refractoriness. To this end, LightIntegra created ThromboLUX, a rapid in-vitro test that provides sizedistribution information for microparticles in blood products. As a routine test for platelet concentrates, ThromboLUX may identify which platelet units would be best suited for prophylaxis and which units are better suited for therapeutic use. Her years of research on platelet function led to a breakthrough discovery using dynamic light scattering to characterize platelets. Dr. Maurer recognized the opportunity to use this breakthrough - coupled with advances in laser and optics technology – to address a market need to provide a safe, quick and simple diagnostic test for microparticles, platelet quality and function. $370.1K / Venture - Series Unknown / Jun 02, 2020
Sonic Incytes Sonic Incytes
Sonic Incytes is a medical device start-up company developing quantitative ultrasound for point-of-care diagnostic and procedure guidance. our mission to enable routine assessment and management of liver health, with diagnostic accuracy you can count on. $2.5M / Seed / May 28, 2020
BarrelWise Technologies BarrelWise Technologies
BarrelWise Technologies creates technology to improve wine production and analysis, with products used by wineries in British Columbia, California, and Washington. The FS1 System, the company's flagship product, enables wineries to bring routine free SO2 checks to the cellar, reducing the process from days to minutes while maintaininglab-level accuracy. Seed / Apr 16, 2020
Acuva Technologies Acuva Technologies
Acuva Technologies is developing ultraviolet light emitting diode (UV-LED) based drinking water purification systems targeting low to moderate volumes of water in various sizes. Acuva’s reactor is a compact, modular, and scalable system comprising UV LEDs, to provide a dose of UV radiation to water flowing through the device. The UV puriicationsystem obtains germicidal destruction of biological contaminants such as viruses and bacteria. $1M / Series B / Sep 30, 2019
See all 12 investments →

Co-Investors

E-Fund E-Fund 4 deals together Echo River Capital Echo River Capital 2 deals together
Elemental Impact Elemental Impact 2 deals together
Elemental Impact Elemental Impact 2 deals together
Jetstream Jetstream 2 deals together
NEC X NEC X 2 deals together

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
Google
Clean Energy
EdTech
Artificial Intelligence
Local
Enterprise Software
Travel
Platforms
InsurTech
Retail
Oil and Gas
Social Impact
Cryptocurrency
SaaS
Film
Restaurants
Photography
Payments
Email
CleanTech
Energy
Marketplace
Organic Food
Fitness
Machine Learning
Health Care
Agriculture (AgTech)
Gaming
Facebook
Social Network
Blockchain
B2B
Video Games
Big Data
Medical Device
Wellness
Education
Mobile
Automotive
Sports
Legal
eSports
Construction
Hospitality
Biotechnology
Consumer
Software
Renewable Energy
Crowdfunding
Venture Capital
Fashion
Social
Beauty
Infrastructure
Cannabis
LGBT
Celebrity
Climate
Mobile Apps
Life Science
Wine and Spirits
Food and Beverage
Theatre
Publishing
Music
Art
Real Estate
Sporting Goods
Medical
Manufacturing
Digital Media
FinTech
Recruiting
Finance
Financial Services
Social Media
Franchise
Web3
Mobile Advertising
Non Profit
Android
Internet
Sustainability
Hardware
Biotech
Impact
Proptech
Enterprise
Transportation
Community
Media (Entertainment)
Any country
Hong Kong
Thailand
United Arab Emirates
Egypt
Greece
Croatia
Burkina Faso
South Korea
Singapore
Brazil
Kyrgyzstan
LATAM
Africa
Oceania
Gibraltar
Liberia
Taiwan
Tunisia
Mexico
Sweden
Nigeria
Russian Federation
Togo
Zimbabwe
Guinea
Nepal
Zambia
Iran
Isle of Man
Norway
Madagascar
Pakistan
Tajikistan
Romania
Poland
Oman
Puerto Rico
Andorra
Cameroon
Guernsey
Sudan
Colombia
China
Armenia
Czech Republic
Costa Rica
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Mauritius
Nicaragua
Panama
Namibia
Serbia
Uzbekistan
New Zealand
Australia
Saudi Arabia
Sri Lanka
Jamaica
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Malawi
Myanmar
Uganda
Turkey
Uruguay
Morocco
Moldova
Paraguay
Seychelles
Botswana
Ireland
Japan
South Africa
France
Georgia
Denmark
Ghana
Iraq
Canada
Mali
Latvia
Malaysia
United Kingdom
Portugal
Philippines
Sierra Leone
Rwanda
El Salvador
Senegal
Tanzania
United States
Germany
India
Indonesia
Middle East
Asia
Dominican Republic
Bermuda
Spain
Albania
Argentina
Angola
Bangladesh
Europe
Cyprus
Belgium
Barbados
Jordan
Austria
Ethiopia
Azerbaijan
Bulgaria
Ecuador
Bahamas
Faroe Islands
Estonia
Jersey
Bahrain
Bolivia
Algeria
Belize
Finland
Italy
Belarus
Hungary
Grenada
Israel
Iceland
Cambodia
Honduras
Lithuania
Liechtenstein
Lebanon
Mongolia
Qatar
Peru
Slovenia
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does Genome British Columbia invest in?

Genome British Columbia invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Seed and Grant stage. Most of the 12 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.

What is Genome British Columbia's check size?

Genome British Columbia typically joins rounds of $1.8M–$4.7M at Seed. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Genome British Columbia participates in.

How do I contact Genome British Columbia?

Public channels for Genome British Columbia include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

Who are the partners at Genome British Columbia?

The team at Genome British Columbia includes Tony Brooks (CFO& VP Entrepreneurship & Commercialization), Catalina Lopez-Correa (Chief Scientific Officer & Vice President Sectors) and Federica Di Palma (Chief Scientific Officer and Vice President Sectors). The Team section lists each member with their title, investment count and links.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
Genome British Columbia Genome British Columbia Find emails